Intelligence Feed event · Equity · 2026-10-07

    Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout

    Question

    Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout

    Direct answer

    Biopharmaceutical firm Oculis announced its clinical presentation schedule for Eyecelerator @ AAO 2026, where executive leadership will review Licaminlimab. The company reiterated that its primary registrational trial, PREDICT-1, is proceeding toward a topline clinical readout before the close of 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/oculis-to-present-licaminlimab-data-ahead-of-year-end-registrational-readout-0e890d

    EQUITY
    Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout
    Biopharmaceutical firm Oculis announced its clinical presentation schedule for Eyecelerator @ AAO 2026, where executive leadership will review Licaminlimab. The company reiterated that its primary registrational trial, PREDICT-1, is proceeding toward a topline clinical readout before the close of 2026.
    OCS
    Impact
    56
    OCT 7
    SIG
    82%
    OCS
    Oculis to Present Licaminlimab Data Ahead of Year-End Registrational Readout
    Biopharmaceutical firm Oculis announced its clinical presentation schedule for Eyecelerator @ AAO 2026, where executive leadership will review Licaminlimab. The company reiterated that its primary registrational trial, PREDICT-1, is proceeding toward a topline clinical readout before the close of 2026.
    → Registrational trial timeline confirmation and mechanism presentation establish pipeline commercial potential for OCS equity valuation.
    Impact
    Biopharmaceutical firm Oculis announced its clinical presentation schedule for Eyecelerator @ AAO 2026, where executive leadership will review Licaminlimab. The company reiterated that its primary registrational trial, PREDICT-1, is proceeding toward a topline clinical readout before the close of 2026.
    Affected
    OCS
    Transmission
    Registrational trial timeline confirmation and mechanism presentation establish pipeline commercial potential for OCS equity valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    OCSbiotech clinical pipeline de-risking ahead of Phase 3 topline readoutUp1-3mOculis reiterated that PREDICT-1 registrational trial is on track for year-end readout.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month